BioSavita’s drug development programs have been funded by National Institutes of Health SBIR grants and are available for co-development.

We have developed a rapid and cost effective yeast platform which can be used to produce vaccines and antibodies against Ebola and other infectious disease agents. Our lead programs also include other products for biodefense such as a recombinant human enzyme to treat nerve gas poisoning.